Key points are not available for this paper at this time.
Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor. (Funded by Astellas Pharma US and Seagen; EV-301 ClinicalTrials.gov number, NCT03474107.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Powles et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69cb458e99b1cc16ab028e04 — DOI: https://doi.org/10.1056/nejmoa2035807
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Thomas Powles
Jonathan E. Rosenberg
Guru Sonpavde
New England Journal of Medicine
Harvard University
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...